Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly patients with acute myeloid leukemia (AML) in relapse. Nevertheless, no data are until now available concerning the possible efficacy of GO for myeloid sarcomas ( MS). We treated with GO 24 AML patients, in 5 cases presenting with myeloid sarcomas of the skin or bones. The overall complete response rate was 21%. The median duration of response was 6 months. Four out of the 5 patients with myeloid sarcoma showed a regression of the masses, in two cases also obtaining a clearance of marrow blasts. The most common adverse events included thrombocytopenia, neutropenia, infections, elevation of bilirubin and hepatic transaminases. Notably, severe bleeding occurred in 5 cases ( 21%). VOD was documented in 1 case. We conclude that GO is effective as a single agent in AML and myeloid sarcomas. Further data are required to clarify the possible correlation between GO administration and occurrence of bleeding.

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas / Piccaluga, Pp; Martinelli, G; Rondoni, M; Malagola, M; Gaitani, S; Isidori, A; Bonini, A; Gugliotta, L; Luppi, Mario; Morselli, M; Sparaventi, G; Visani, G; Baccarani, M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 45:9(2004), pp. 1791-1795. [10.1080/1042819042000219485]

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

LUPPI, Mario;
2004

Abstract

Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly patients with acute myeloid leukemia (AML) in relapse. Nevertheless, no data are until now available concerning the possible efficacy of GO for myeloid sarcomas ( MS). We treated with GO 24 AML patients, in 5 cases presenting with myeloid sarcomas of the skin or bones. The overall complete response rate was 21%. The median duration of response was 6 months. Four out of the 5 patients with myeloid sarcoma showed a regression of the masses, in two cases also obtaining a clearance of marrow blasts. The most common adverse events included thrombocytopenia, neutropenia, infections, elevation of bilirubin and hepatic transaminases. Notably, severe bleeding occurred in 5 cases ( 21%). VOD was documented in 1 case. We conclude that GO is effective as a single agent in AML and myeloid sarcomas. Further data are required to clarify the possible correlation between GO administration and occurrence of bleeding.
2004
45
9
1791
1795
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas / Piccaluga, Pp; Martinelli, G; Rondoni, M; Malagola, M; Gaitani, S; Isidori, A; Bonini, A; Gugliotta, L; Luppi, Mario; Morselli, M; Sparaventi, G; Visani, G; Baccarani, M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 45:9(2004), pp. 1791-1795. [10.1080/1042819042000219485]
Piccaluga, Pp; Martinelli, G; Rondoni, M; Malagola, M; Gaitani, S; Isidori, A; Bonini, A; Gugliotta, L; Luppi, Mario; Morselli, M; Sparaventi, G; Visani, G; Baccarani, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/4364
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 52
social impact